EXCLUSIVE LICENSE AND ASSET PURCHASE AGREEMENTExclusive License and Asset Purchase Agreement • August 4th, 2017 • Immunogen Inc • Pharmaceutical preparations • New York
THIS EXCLUSIVE LICENSE AND ASSET PURCHASE AGREEMENT (this “Agreement”) is made effective as of May 23, 2017 (the “Effective Date”) by and between Debiopharm International, S.A., a Swiss limited company (“Debiopharm”) having a place of business at Forum “après-demain,” Chemin Messidor 5-7, Case Postale 5911, CH-1002 Lausanne, Switzerland, and ImmunoGen, Inc., a Massachusetts corporation (“ImmunoGen”) having a place of business at 830 Winter Street, Waltham, MA 02451-1477, U.S.A. ImmunoGen and Debiopharm are sometimes each hereinafter referred to as a “Party” and collectively as the “Parties”.
